Halozyme Therapeutics (HALO) EBITDA (2010 - 2026)
Halozyme Therapeutics' EBITDA was $321.67 million in Q2 2026, up 44.3% from $222.9 million a year earlier and up 47.4% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) EBITDA (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Halozyme Therapeutics' EBITDA was $712.08 million through Jun 30, 2026, down 6.8% year-over-year; for FY2025, it came in at $557.07 million, down 12.0% from FY2024.
- EBITDA shows a five-year compound annual growth rate of 30.4% (FY2020 to FY2025).
- In earlier years, EBITDA was $632.82 million in FY2024 (+49.8%), $422.45 million in FY2023 (+33.2%), $317.18 million in FY2022 (+13.7%) and $278.9 million in FY2021 (+89.0%).
- The Q2 2026 figure marks the highest quarterly EBITDA in data going back to Q3 2010.
- The best year-over-year quarter for EBITDA over five years was Q2 2023 (growth of 147.2%); the worst was Q2 2022 (a decline of 50.4%).
- Per Business Quant data, HALO's EBITDA in the three quarters before Q2 2026 was $218.25 million (Q1 2026), -$66.22 million (Q4 2025) and $238.38 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 12.29 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 9.10 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 8.33 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 999.00 Mn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 5.09 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 4.63 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | -9.70 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 5.89 Bn |
| 10 | Halozyme Therapeutics | 14.59 Bn | 13.20 Bn | 401.83 Mn | 323.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 323.92 Mn |
| Mar 31, 2026 | 220.50 Mn |
| Dec 31, 2025 | -64.27 Mn |
| Sep 30, 2025 | 240.24 Mn |
| Jun 30, 2025 | 224.76 Mn |
| Mar 31, 2025 | 163.84 Mn |
| Dec 31, 2024 | 197.80 Mn |
| Sep 30, 2024 | 185.40 Mn |
| Jun 30, 2024 | 139.43 Mn |
| Mar 31, 2024 | 117.58 Mn |
| Dec 31, 2023 | 123.53 Mn |
| Sep 30, 2023 | 113.14 Mn |
| Jun 30, 2023 | 116.91 Mn |
| Mar 31, 2023 | 76.09 Mn |
| Dec 31, 2022 | 83.46 Mn |
| Sep 30, 2022 | 116.41 Mn |
| Jun 30, 2022 | 47.67 Mn |
| Mar 31, 2022 | 77.44 Mn |
| Dec 31, 2021 | 58.28 Mn |
| Sep 30, 2021 | 77.25 Mn |
API Access
Halozyme Therapeutics EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();